Department of Neurological Surgery, Columbia University Medical Center, New York, New York, USA.
Neuro Oncol. 2011 Aug;13(8):886-93. doi: 10.1093/neuonc/nor051. Epub 2011 Jul 12.
Intracerebral convection-enhanced delivery (CED) of chemotherapeutic agents currently requires an externalized catheter and infusion system, which limits its duration because of the need for hospitalization and the risk of infection. To evaluate the feasibility of prolonged topotecan administration by CED in a large animal brain with the use of a subcutaneous implantable pump. Medtronic Synchromed-II pumps were implanted subcutaneously for intracerebral CED in pigs. Gadodiamide (28.7 mg/mL), with or without topotecan (136 μM), was infused at 0.7 mL/24 h for 3 or 10 days. Pigs underwent magnetic resonance imaging before and at 6 times points after surgery. Enhancement and FLAIR+ volumes were calculated in a semi-automated fashion. Magnetic resonance spectroscopy-based topotecan signature was also investigated. Brain histology was analyzed by hematoxylin and eosin staining and with immunoperoxidase for a microglial antigen. CED of topotecan/gadolinium was well tolerated in all cases (n = 6). Maximum enhancement volume was reached at day 3 and remained stable if CED was continued for 10 days, but it decreased if CED was stopped at day 3. Magnetic resonance spectroscopy revealed a decrease in parenchymal metabolites in the presence of topotecan. Similarly, the combination of topotecan and gadolinium infusion led to a FLAIR+ volume that tended to be larger than that seen after the infusion of gadolinium alone. Histological analysis of the brains showed an area of macrophage infiltrate in the ipsilateral white matter upon infusion with topotecan/gadolinium. Intracerebral topotecan CED is well tolerated in a large animal brain for up to 10 days. Intracerebral long-term CED can be achieved with a subcutaneously implanted pump and provides a stable volume of distribution. This work constitutes a proof of principle for the safety and feasibility for prolonged CED, providing a means of continuous local drug delivery that is accessible to the practicing neuro-oncologist.
脑内对流增强递送(CED)化疗药物目前需要外部化的导管和输注系统,由于需要住院治疗和感染风险,因此其持续时间受到限制。本研究旨在评估使用皮下植入式输液泵在大型动物脑中进行延长拓扑替康 CED 的可行性。在猪中使用 Medtronic Synchromed-II 输液泵进行脑内 CED。以 0.7 mL/24 h 的速度输注 28.7 mg/mL 的钆喷酸葡胺,或同时输注 136 μM 的拓扑替康,持续 3 或 10 天。在手术前后的 6 个时间点对猪进行磁共振成像。以半自动方式计算增强和 FLAIR+体积。还通过磁共振波谱研究了拓扑替康特征。通过苏木精和伊红染色以及免疫过氧化物酶分析对脑组织进行分析,检测小胶质细胞抗原。在所有情况下(n=6),均能很好地耐受 CED 拓扑替康/钆。最大增强体积在第 3 天达到峰值,如果 CED 持续 10 天则保持稳定,但如果在第 3 天停止 CED 则会降低。磁共振波谱显示存在拓扑替康时脑实质代谢物减少。同样,拓扑替康和钆输注的组合导致 FLAIR+体积倾向于大于单独输注钆的体积。对大脑的组织学分析显示,在输注拓扑替康/钆后,同侧白质中有巨噬细胞浸润区。在大型动物脑内,颅内长期 CED 可耐受长达 10 天。通过皮下植入的泵可以实现颅内长期 CED,并提供稳定的分布体积。这项工作为延长 CED 的安全性和可行性提供了原理证明,为神经肿瘤学家提供了一种可实现的持续局部药物输送方法。